Adding Atezolizumab to mFOLFOX6 Improves DFS Among Patients with Stage III dMMR Colon Cancer By Ogkologos - March 31, 2026 182 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ATOMIC study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR How Pelvic Floor Therapy Can Help People With Prostate Cancer and... December 13, 2022 FDA Approves Capivasertib with Abiraterone and Prednisone for PTEN-deficient Androgen Pathway... July 15, 2026 Rucaparib Extends PFS in the Maintenance Treatment of Recurrent EOC Without... September 1, 2020 Efficacy of Taletrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC April 18, 2025 Load more HOT NEWS Sevabertinib Shows Antitumour Activity in Patients with Locally Advanced or Metastatic... Less Frequent Mammographic Surveillance Non-inferior Compared with Annual Mammograms After Diagnosis... Enfortumab Vedotin Plus Pembrolizumab Shows a High Confirmed Objective Response Rate... Connecting and Celebrating
